基于生物信息学方法分析MFAP2基因在胃癌预后及免疫治疗中的意义OA北大核心CSTPCD

Objective:To screen the key genes affecting the prognosis and treatment of gastric cancer(GC)patients and to analyze the value of the key gene microfibrillar-associated protein 2(MFAP2)in suggesting the prognosis and the sensitivity of immunotherapy of GC patients.Methods:The expression profile data and clinical information of gastric cancer and paracancerous tissues were downloaded from the TCGA database.Genes significantly associated with the prognosis of gastric cancer were screened by weighted gene co-expression network analysis(WGCNA)and univariate Cox regression analysis.Multiple patient cohorts were used to assess the prognostic value of the key gene MFAP2 and analyze its efficacy and clinicopathological correlation.Multiple online databases and algorithms were used to analyze the correlation between MFAP2 and the tumor immune microenvironment.Immunophenotyping score(IPS)combined with immunotherapy patient cohort was used to analyze the value of MFAP2 in predicting the responsiveness of immunotherapy.Differential expression of MFAP2 in gastric cancer and adjacent tissues was verified with multiple datasets.Results:The blue module showed the highest correlation with survival outcomes of GC patients(R=0.17,P<0.001).Further intersections were taken with prognosis-related genes,and a total of 20 key genes were screened.High expression of the key gene MFAP2 suggested poor prognosis and pathological progression of GC(HR>1,P<0.05).MFAP2 was closely associated with cancer-associated fibroblasts,and GC patients with high expression of MFAP2 were more insensitive to immunotherapy.The high expression of MFAP2 mRNA in GC was verified by multiple datasets(P<0.05 or P<0.01).Conclusion:High expression of MFAP2 is a predictive factor for poor prognosis and response to immunotherapy in GC patients.MFAP2 is expected to serve as a novel therapeutic target and prognostic indicator for gastric cancer.